MODIFIED METHODS OF DRUG DELIVERY IN MODERN ONCOLOGY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper considers new directions in the medical treatment of neoplasms. Special attention is paid to the targeted transport of drugs through various carriers as the most promising area of chemotherapy.

Full Text

Restricted Access

About the authors

A. Zaborovsky

Moscow State University of Medicine and Dentistry

Email: azabor@mail.ru
Candidate of Medical Sciences

K. Gurevich

Moscow State University of Medicine and Dentistry

Professor

E. Lobanova

Moscow State University of Medicine and Dentistry

Professor

I. Krysanov

Institute of Socomedical Technologies

Candidate of Pharmaceutical Sciences

L. Tararina

Moscow State University of Medicine and Dentistry

D. Yunina

Moscow State University of Medicine and Dentistry

References

  1. Fitzmaurice C., Allen C., Barber R. et al. Global Burden of Disease Cancer Collaboration // JAMA Oncol. - 2016; doi: 10.1001/jamaoncol.2016.5688.
  2. Cronin P., Kirkbride B., Bang A. et al. Long-term health care costs for patients with prostate cancer: A population-wide longitudinal study in New South Wales, Australia // Asia Pac. J. Clin. Oncol. - 2016; doi: 10.1111/ajco.12582.
  3. Jones J., Olson K., Catton P. et al. Cancer-related fatigue and associated disability in post-treatment cancer survivors // J. Cancer Surviv. - 2016; 10 (1): 51-61. doi: 10.1007/s11764-015-0450-2
  4. Чиссов В.И. Онкология. Нац. руководство / М.: ГЭОТАР-Медиа, 2008; 1060 с.
  5. Хвастунов Р.А., Скрыпникова Г.В., Усачев А.А. Таргетная терапия в онкологии // Лекарств. вестник. - 2014; 8 (56): 3-10.
  6. Юркин А.К., Тыренко В.В., Максимов А.Г. и др. Сравнительная характеристика показателей крови в динамике лечения больных злокачественными лимфомами // Вест. Рос. военно-мед. академии. - 2016; 2 (54): 28-33.
  7. Mandrekar S., Dy G., Furth A. et al. Complementary and alternative medicine (CAM) use by patients enrolled in phase I clinical trials // J. Clin. Oncol. - 2004; 22 (suppl. 14): 8053.
  8. Blunt J., Copp B., Keyzers R. et al. Marine natural products // Nat. Prod. Rep. - 2013; 30 (2): 237-323. doi: 10.1039/c2np20112g. Review.
  9. Ghaly P., Abou El-Magd R., Churchill C. et al. A new antiproliferative noscapine analogue: chemical synthesis and biological evaluation // Oncotarget. -2016; 7 (26): 40518-30. doi: 10.18632/oncotarget.9642.
  10. Лагунин А.А., Дружиловский Д.С., Рудик А.В. и др. Возможности компьютерной оценки скрытого потенциала фитокомпонентов лекарственных растений из традиционной индийской медицины Аюрведа // Биомед. химия. - 2015; 61 (2): 286-97.
  11. Hadjiandreou M., Mitsis G. Mathematical modeling of tumor growth, drug-resistance, toxicity, and optimal therapy design // IEEE Trans Biomed Eng. - 2014; 61 (2): 415-25.
  12. Maurel J., Postigo A. Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice // Curr. Cancer Drug Targets. - 2015; 15 (8): 703-15.
  13. Cheng Y., Zhang A., Hu J. et al. Multifunctional Peptide-Amphiphile End-Capped Mesoporous Silica Nanoparticles for Tumor Targeting Drug Delivery // ACS Appl Mater Interfaces. - 2016; doi: 10.1021/acsami.6b12647.
  14. Rosen L., Gordon M., Bai S. et al. A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors // J. Clin. Oncol. - 2011; 29 (Suppl. 15): 2614.
  15. Трещалин И.Д., Переверзева Э.Р., Бодягин Д.А. и др. Модификация токсичности противоопухолевых препараратов как метод повышения эффективности химиотерапии злокачественных новообразований // Рос. биотерапевт. журн. - 2005; 4 (3): 87-94.
  16. Kirtane A., Kalscheuer S., Panyam J. Exploiting nanotechnology to overcome tumor drug resistance: challenges and opportunities // Adv. Drug Deliv. Rev. - 2013; 65 (13-14): 1731-47. doi: 0.1016/j.addr.2013.09.001. Epub 2013 Sep 10.
  17. Gabizon A., Patil Y., La-Beck N. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy // Drug Resist. Updat. - 2016; 29: 90-106. doi: 10.1016/j.drup.2016.10.003.
  18. Крысанов И.С. Фармакоэкономический анализ применения липосомального пегилированного доксорубицина (Келикс) для лечения метастатического рака молочной железы у больных с повышенным риском кардиологических осложнений // Качественная клин. практика. - 2016; 1: 25-32.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies